Systematic review with meta‐analysis : comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials
Systematic review with network meta‐analysis : comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease
Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies
The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease
The dynamics of the oesophageal squamous epithelium ‘normalisation’ process in patients with gastro‐oesophageal reflux disease treated with long‐term acid suppression or anti‐reflux surgery
Diagnosis of gastro‐oesophageal reflux disease is enhanced by adding oesophageal histology and excluding epigastric pain
Functional dyspepsia is associated with duodenal eosinophilia in an Australian paediatric cohort
Editorial : clinical benefits of vitamin D therapy in inflammatory bowel disease
Editorial : inflammatory bowel disease risk reduction after migration – are early life events important?
Editorial : Clostridium difficile and inflammatory bowel disease – is it always a bad combination?
Editorial : importance of definition of inflammatory bowel disease and an increased incidence in children
Editorial : CT‐P13, a biosimilar of anti‐tumour necrosis factor‐alpha agent (infliximab), in inflammatory bowel diseases
Editorial : CT‐P13, a biosimilar of anti‐tumour necrosis factor‐alpha agent (infliximab), in inflammatory bowel diseases – authors’ reply
Editorial : hepatitis B reactivation in patients with chronic hepatitis C treated with direct‐acting antivirals – incidence, severity of hepatitis and lessons to learn
Editorial : accumulating data about ustekinumab in refractory Crohn's disease in real world experience
Letter : chronic hepatitis C genotype 3 infection – still a hurdle toward a direct‐acting anti‐viral‐induced HCV cure?